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Non-steroidal anti-inflammatory drug 37 prepared carbomer hydrogels (HG_PF-F1NPs and HG_PF-F2NPs) or in hydrogels containing 1% azone 43 (HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone) in order to improve the ocular biopharmaceutical profile 44 of the selected non-steroidal anti-inflammatory drug (NSAID), by prolonging the contact of the pranopro- 45 fen with the eye, increasing the drug retention in the organ and enhancing its anti-inflammatory and 46 analgesic efficiency. Carbomer 934 has been selected as gel-forming polymer. The hydrogel formulations 47 with or without azone showed a non-Newtonian behavior and adequate physicochemical properties for 48 ocular instillation. The release study of pranoprofen from the semi-solid formulations exhibited a sus- ticularly when exposed to light [6, 7] . Pranoprofen is commercially Abbreviations: PF, pranoprofen; NPs, nanoparticles; HG, hydrogel; PF-F1NPs and PF-F2NPs, optimize pranoprofen nanoparticles; HG_PF-NPs-Azone and HG_PF-NPs, nanoparticles incorporated into hydrogel with and without azone, respectively; Z-Ave, average particle size; PI, polydispersity index; ZP, zeta potential; EE, entrapment efficiency; PVA, polyvinyl alcohol; cPF, PF concentration; cPVA, PVA concentration; PLGA, poly-L-lactic-co glycolic acid; cPLGA, PLGA concentration; SA, arachidonic acid sodium; PBS, phosphate buffer solution; BR, Bicarbonate Ringer; Q P , amounts of drug permeated across cornea; Q R , amounts of drug retained in the cornea.
75
age form cannot be considered optimal in the treatment of ocular 76 diseases due to the fact that upon instillation most of the drugs 77 are removed from the surface of the eye, by various mechanisms 78 (tear dilution and tear turn over). Moreover, the relatively imper-79 meable corneal barrier restricts the entry of foreign substances.
80
As a result, less than 5% of the administered drug penetrates the 81 cornea and reaches intraocular tissue [8] profen released was measured as described previously for EE. ues are reported as the mean ± SD of three replicates.
284
The amount pranoprofen release was adjusted to the following 285 kinetic models [27] :
First order :
Higuchi : This compartment was kept at 37 ± 0.5°C and stirred continuously. following equations: The anti-inflammatory efficacy of the HG_PF-NP formulations 414 was assessed using the method described by Spampinato Santi 415 et al. [34] , the ocular inflammation was induced by ocular instilla- Table 3 . measurements applied to the formulations showed the prevalence Fig. 1 . Transmission electron microphotograph of the optimized NPs incorporated into hydrogel.
Table 2
Mean particle size (Z-Ave) and zeta potential (ZP) of the HG_PF-NP formulations 1 day after production and after 90 days of storage at 25°C. Table 5 . 598 At the end of the corneal permeation study, the cornea was used 599 to determine the amount of drug retained and the corneal hydra-600 tion level. These results are exhibited in Table 6 . and free drug for the P 1 parameter. As shown in Table 5 n, diffusional release exponent; AIC, Akaike information criterion. Results are reported as median value and minimum -maximum range values (Q P , n = 6; Q R , n = 3; HL, n = 3).
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